← Human Trials & Peer-Reviewed Studies
Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial
Plain-language guide to PMID 39858442 (2025): randomized controlled trial study of Semaglutide in 31 patients, psoriasis and psoriatic arthritis.
Key Facts
- PMID
- 39858442
- Journal
- Biomolecules
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Petković-Dabić J et al. (11 authors)
- DOI
- 10.3390/biom15010046
What This Study Did, in Plain Language
What Was Tested
Researchers studied Semaglutide in the context of psoriasis and psoriatic arthritis in this randomized controlled trial publication.
The objective of this clinical study was to investigate the effect of GLP-1 receptor agonist semaglutide therapy on pro-inflammatory factors in the serum and the severity of the clinical picture of psoriasis in obese patients with type 2 diabetes mellitus (T2DM) on chronic metformin therapy.
Why It Was Studied
Psoriasis is a chronic inflammatory skin disease with relapsing nature.
More severe forms of psoriasis are conditions of high inflammation, which is confirmed by the clinical picture and numerous inflammatory parameters such as C-reactive protein (CRP), cytokines and homocysteine, which vary with disease activity.
Who Took Part
The study group was 31 patients.
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (n = 15), while the second was control (n = 16).
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.
What Was Measured
The subject headings attached to it are Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Psoriasis, Obesity, Metformin, C-Reactive Protein and Glucagon-Like Peptide 1.
The authors tagged it with the keywords DLQI, PASI, T2DM, cytokine and semaglutide.
What This Means in Plain Language
The paper is a randomized study of Semaglutide in 31 patients in people with psoriasis and psoriatic arthritis.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2025 (Biomolecules), a journal based in Switzerland.
More context: the Semaglutide compound page, Psoriasis and psoriatic arthritis research.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.